Steroids and drotrecogin alfa (activated) for severe sepsis

被引：0
|
作者：
Steingrub, JS [1 ]
机构：
[1] Baystate Med Ctr, Med ICU, Springfield, MA 01199 USA
来源：
CHEST | 2003年 / 124卷 / 05期
关键词：
D O I：
10.1378/chest.124.5.2033
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：2033 / 2033
页数：1
相关论文
共 50 条
  • [41] Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)
    Levi, Marcel
    Levy, Mitchell
    Williams, Mark D.
    Douglas, Ivor
    Artigas, Antonio
    Antonelli, Massimo
    Wyncoll, Duncan
    Janes, Jonathan
    Booth, Frank V.
    Wang, Dazhe
    Sundin, David P.
    Macias, William L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (05) : 483 - 490
  • [42] A comparison of drotrecogin alfa (activated) in medical and surgical patients with severe sepsis
    Miles, W
    Sturdevant, M
    Huynh, T
    Thomason, M
    Jacobs, D
    Sing, R
    Forshag, M
    Settlemyer, J
    Martin, T
    CRITICAL CARE MEDICINE, 2003, 31 (12) : A128 - A128
  • [43] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, G
    van Hout, B
    CRITICAL CARE MEDICINE, 2003, 31 (01) : 1 - 11
  • [44] Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis
    Bernard, GR
    CRITICAL CARE MEDICINE, 2003, 31 (01) : S85 - S93
  • [45] Use of drotrecogin alfa (activated) in a severe acute respiratory syndrome patient with severe sepsis
    McRitchie, Donna
    Farooq, Warda
    Fisher, Harold N.
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2008, 19 (03): : 258 - 259
  • [46] Drotrecogin alfa (activated): Surviving sepsis by chance
    Levi, Marcel
    Levy, Mitchell
    Williams, Mark D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (06) : 669 - 670
  • [47] Drotrecogin alfa (activated) in the management of sepsis - Introduction
    Boucher, BA
    Olsen, KM
    PHARMACOTHERAPY, 2002, 22 (12): : 167S - 168S
  • [48] Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany
    Neilson, AR
    Burchardi, H
    Chinn, C
    Clouth, J
    Schneider, H
    Angus, D
    JOURNAL OF CRITICAL CARE, 2003, 18 (04) : 217 - 227
  • [49] Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
    Davies, A
    Ridley, S
    Hutton, J
    Chinn, C
    Barber, B
    Angus, DC
    ANAESTHESIA, 2005, 60 (02) : 155 - 162
  • [50] Drotrecogin alfa (activated) in severe sepsis patients with 2 or more organ dysfunctions
    Dhainaut, J
    Laterre, P
    Basson, B
    Vincent, J
    INTENSIVE CARE MEDICINE, 2002, 28 : S82 - S82
12345